Cancer Therapy

Data presented on GEM231, second-generation antisense compound

Published in Cancer Weekly, August 5th, 2003

Hybridon, Inc., (HYBN) announced the presentation of data from the phase I clinical trial of GEM231, the company's second-generation antisense compound for treating solid tumor cancers.

The presentation by Dr. Sanjay Goel of the Albert Einstein Medical Center, entitled "Extracellular Protein Kinase A (ECPKA) assay in cancer patients treated with multi-day continuous intravenous infusions (CIV) of GEM231, a second-generation antisense oligonucleotide targeting the PKA RIalpha subunit," was made at the 94th annual meeting of the American Association for Cancer Research being held in Washington, DC.

The study was designed to evaluate safety and effects...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry